Equities

Immunotech Biopharm Ltd

Immunotech Biopharm Ltd

Actions
  • Price (HKD)1.80
  • Today's Change-0.02 / -1.10%
  • Shares traded480.00k
  • 1 Year change-52.88%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 07:34 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments17879353
Total Receivables, Net------
Total Inventory4.927.2111
Prepaid expenses313148
Other current assets, total0.260.260.26
Total current assets214118412
Property, plant & equipment, net501527427
Goodwill, net------
Intangibles, net424214
Long term investments46140163
Note receivable - long term------
Other long term assets------
Total assets8468791,098
LIABILITIES
Accounts payable463732
Accrued expenses101618
Notes payable/short-term debt000
Current portion long-term debt/capital leases252620
Other current liabilities, total123129110
Total current liabilities203208180
Total long term debt43212491
Total debt457150111
Deferred income tax------
Minority interest(2.73)(2.07)0.92
Other liabilities, total39413.56
Total liabilities673371275
SHAREHOLDERS EQUITY
Common stock3.583.583.58
Additional paid-in capital1,4021,4021,402
Retained earnings (accumulated deficit)(1232)(898)(584)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity174508822
Total liabilities & shareholders' equity8468791,098
Total common shares outstanding515515515
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.